多年来,生物制剂的口服给药一直被认为不切实际。但是如果问题不在于给药途径本身,而在于我们采用的方法是否得当?
In our new podcast, Lonza Capsugel’s Vincent Jannin, R&D expert, discusses how using strategies that work with gastrointestinal physiology, rather than fighting against it, opens new possibilities for clinically and commercially viable oral dosage forms.
From peptides to emerging modalities, the conversation challenges long-standing assumptions and highlights how integrated capsule and formulation technologies are redefining what is possible.
Listen to the full discussion and discover how we’re turning oral biologics into strategic opportunity.
* The presented information was correct and current at the time of publication.
Latest CHI content